Trial reportClinical and experimental nephrology2008
Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia.
Trial report in Clinical and experimental nephrology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.PloS one · 2014Pooled it
- Lipid-lowering agents for nephrotic syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Red yeast rice with monacolin K for the improvement of hyperlipidemia: A narrative review.World journal of clinical cases · 2025Review
- 2024 update on postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia.Archives of medical science : AMS · 2025Article
- Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review.Nutrients · 2023Review
- Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice.Chinese medicine · 2022Article
- Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia.Archives of medical science : AMS · 2021Article
- Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.Nature reviews. Nephrology · 2018Review
- Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action.Frontiers in pharmacology · 2016Review
- Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia.P & T : a peer-reviewed journal for formulary management · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsNephrotic dyslipidemia is a risk factor for the development of systemic atherosclerosis; it may also aggravate glomerulosclerosis and enhance the progression of glomerular disease. We aimed to assess the efficacy and safety of Monascus purpureus Went rice versus fluvastatin therapy in the management of nephrotic dyslipidemia.
methodsIn total 72 patients with idiopathic persistent NS with secondary dyslipidemia were included. They were randomly allocated into three age- and sex-matched groups. The first group comprised 20 cases that were given M. purpureus Went rice in a dose of 600 mg twice per day for one month and then once daily. The second group comprised 30 cases that were given fluvastatin in a daily dose of 20 mg. The remaining 22 received no antidyslipidemic therapy and constituted a control group. All of these patients were subjected to thorough laboratory investigations, including renal function tests and lipograms. Moreover, neuromuscular status was evaluated with electromyography and nerve conduction velocity.
resultsOur results showed that both fluvastatin and M. purpureus Went rice were well-tolerated with no evidence of significant side effects, including on neuromuscular function. Both M. purpureus Went rice and fluvastatin significantly reduced cholesterol after six months and one year, respectively.
conclusionMonascus purpureus Went rice is a safe, effective and economic treatment strategy for nephrotic dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.